Forecast models for Tempus AI show alignment between fundamental upside from revenue expansion and technical support at $42.50, creating a probable trading band up to $ Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company that leverages artificial intelligence to advance precision medicine and patient care. Its offerings include next-generation sequencing diagnostics and polymerase chain reaction testing, serving healthcare providers, pharmaceutical companies, and researchers. ​ Exelixis EXEL raised its full-year 2025 financial guidance following strong first-quarter results, driven by higher demand for CABOMETYX and the recent U.S. FDA approval for its use in treating advanced neuroendocrine tumors (NET). The company expects total revenues in the range of $2.25-$2.35 billion (up from the earlier guidance range of $2.15-$2.25 billion). A major factor behind this upward revision was the FDA approval in March 2025 of CABOMETYX for the treatment of advanced pancreatic and extra-pancreatic NET, making it the first and only systemic treatment approved for previously treated NET regardless of tumor site or grade. Additionally, TEM is optimistic about several upcoming clinical milestones in the second half of the year, including pivotal trial readouts for its next-generation therapy zanzalintinib in colorectal and non-clear cell renal cancers. These developments reinforce Exelixis ’ strategy to expand its oncology portfolio and transition into a multi-franchise cancer company. Analysts project Tempus AI's Q3 revenue growth at 18%, which could support a forecasted price target of $48.